ACLY and cardiovascular disorder: Genetic variants that mimic the effects of ATP citrate lyase inhibitors and statins appear to reduce plasma LDL cholesterol levels through the same mechanism of action, and are associated with cardiovascular disease risk for each unit of LDL cholesterol reduction.